8-K current report · filed Nov 4, 2026

Tenaya Therapeutics Inc (TNYA) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1TNYA overview

Short answer

Tenaya Therapeutics Inc (TNYA) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Tenaya’s earnings release covers the quarter ended September 30, 2026.

Tenaya Therapeutics Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Tenaya’s earnings release covers the quarter ended September 30, 2026
  • Exhibit 99.1 contains the financial results and management disclosures relevant to investors

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 net loss $18.9M, or $0.08 per share, improved from $20.3M, or $0.12, year over year
  • Cash $66.8M supports planned operations into Q4 2027, reducing near-term financing pressure but not eliminating funding risk
  • TN-401 received FDA RMAT designation, potentially enabling closer regulatory interaction for PKP2-associated ARVC development
  • Year-end readouts for TN-201 and TN-401 include one-year Cohort 2 data and durability data for Cohort 1
  • TN-301 study-enabling work targets at least one company-sponsored Phase 2 trial in the second half of 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tenaya Therapeutics Inc 8-K filings

Get the next TNYA 8-K as it lands

Follow TNYA for push alerts, or ask the research agent what this filing means.